An Analysis of the Incidence and Severity of Drug-Drug Interactions Between Prescribed Pharmaceuticals and Cannabinoids
Date of Award
Master of Physician Assistant Studies (MPAS)
Physician Assistant Studies
Medications; Cannabinoids; Drug Interactions
The purpose of this research and systematic literature review is to identify the incidence and severity of drug-drug interactions between commonly prescribed medications and cannabinoids. In this review, four databases were searched including PubMed, CINAHL, and Embase from October 1 to January 5, 2019. A variety of key terms were used when searching. Works chosen for review were published after the year 2014, were peer reviewed, and included randomized control trials (RCTs), systematic literature reviews, and meta-analyses. For this review, 9 resources were selected. Much of the research presented shows evidence that medications that are substrates for CYP2C19, CYP2C9 and CYP1A2 are at the greatest risk of interaction with concomitant use of phytocannabinoids or synthetic cannabinoids. Furthermore, caution is recommended with medications metabolized via UGT or CES1, however information is currently limited and further research is necessary. The lack of universal standards for laboratory testing of cannabinoid products call into question the legitimacy of reported results in currently reported research as the contents of many cannabinoid products are inaccurately labeled.
McRae, Jennifer Lee, "An Analysis of the Incidence and Severity of Drug-Drug Interactions Between Prescribed Pharmaceuticals and Cannabinoids" (2020). Physician Assistant Scholarly Project Papers. 80.